If you can't see this message pleas e us e this linkpleas e us e this link FDAs Expedited Programs for Serious Conditions - Drugs and Biologics Friday,

Slides:



Advertisements
Similar presentations
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Advertisements

(Individuals with Disabilities Education Improvement Act) and
Safety Reporting IN Clinical Trials
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
A Blueprint For Clinical Research: Standard Operating Procedures
Strengthening the Medical Device Clinical Trial Enterprise
Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
Biomedical Auditing. The Biomedical Auditor works with medical devices, including in vitro diagnostics and biologics that are regulated as medical devices.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Post Approval Monitoring Program Presented by Carolyn Malinowski Manager, Quality Assurance and Training.
2 nd International ASIA QA FORUM EVENT INFO This event will be a venue for all QA specialists and scientists working in Asia to expand their intellectual.
SAFA- IFAC Regional SMP Forum
Quality System Overview Version Nov 2012 Alfred Medical Research & Education Precinct (AMREP) Austin Hospital © Copyright Nucleus Network 2012.
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Project Human Resource Management
ISO Quality management International Organization for Standardization International Organization for Standardization It addresses various aspects.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Regulatory Overview.
Ensuring Quality in Medical Device Clinical Trials
Regional Plan for Regulatory System For Blood, Blood Components and Blood Products Objective/Target: By 2012 all member states will have in place a functioning.
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
FDA Docket No. 2004N-0133 Themes for Renewal of 21 CFR Part 11 Rule & Guidance by Dr. Teri Stokes, GXP International
UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.
Lecture Topic 4: Good Manufacturing Practices (GMPs)
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Important informations
Prime Responsibility for Radiation Safety
Case Study SummaryChallenges Boston Scientific needed medical translation in different areas in the medical field, including technical, legal and corporate.
Overview of FDA's Regulatory Framework for PET Drugs
11/15/20151 Who We Are: Arunava (Ron) Sanyal, M.Pharm,CQE, RAC CEO/President
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Molecule-to-Market-Place Quality
Dispensary and Administration Site Information Presentation.
Florida Medicaid Update October 2015 Evelyn Leadbetter, MPA HTH Network Services Manager.
Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.
FDA Regulatory and Compliance Symposium
Investigational Devices and Humanitarian Use Devices June 2007.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
The Second Annual Medical Device Regulatory, Reimbursement and Compliance Congress Presented by J. Glenn George Thursday, March 29, 2007 Day II – Track.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
In Partnership with Lorman Education Services. Discover Lorman Education Lorman has been a leading continuing education provider for 28 years, offering.
Research in Practice for Adults: an introduction 1.
FDA’s Patient Advocacy Programs: Patient Representative Program & Patient Network Andrea Furia-Helms, MPH James Valentine, MHS Office of Special Health.
Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods.
Data Privacy and Security Data Privacy Self- Assessment Data Security Self- Assessment Video Tips Privacy Legion Newsletter Home ScreenLanding Screen Data.
Surgeon List
GCP (GOOD CLINICAL PRACTISE)
RAC Regulatory Affairs Certification
FDA's Two New Draft Guidance on Software and Device
Regulation of Medical Devices: Importance of a Globally Harmonized Approach Nicole Taylor Smith, JD September 2017.
Expedited Drug Approval Programs
Preventing Medical Device Recalls
Quality Assurance and Quality Control in Generics
CDRH 2010 Strategic Priorities
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
Overview of ISO 9001:2015 –Quality Management SysteM
Storage and distribution
Presentation transcript:

If you can't see this message pleas e us e this linkpleas e us e this link FDAs Expedited Programs for Serious Conditions - Drugs and Biologics Friday, September 12, 2014 | 10:00 AM PDT | 01:00 PM EDT | Duration : 120 Minutes | Register Now Register Now This webinar will discuss four FDA programs intended to facilitate and expedite development, review and approval of new drugs to address unmet medical needs in the treatment of serious and life- threatening conditions. This includes FDAs newest expedited program Breakthrough Therapies Designation. Besides Breakthrough Therapies Designation also discuss will be Fast Track Designation, Accelerated Approval and Priority Review Designation. These programs are intended to help ensure that therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies benefits justify their risks. Criteria for each expedited program will be reviewed so a judgment can be made relative to your new drug. Also definitions for serious condition and unmet medical need will be covered. Instructor: with all aspects of the FDA approval PRO versionpdfcrowd.com Are you a developer? Try out the HTML to PDF APIHTML to PDF API Albert A. Ghignone Albert A. Ghignone, MS, RAC is the CEO of AAG Incorporated. For more than 30 years his focus has been on FDA related matters in regulatory affairs, quality assurance and clinical affairs. He has expertise in dealing

A must attend webinar for those personnel that require an understanding of the FDAs expedited programs for serious conditions. Areas Covered in the Session : FDAs Expedited Program system Definitions for serious condition and unmet medical need FDAs Breakthrough Therapy Designation Program FDAs Fast Track Designation Program FDAs Priority Review Designation Program FDAs Accelerated Approval Program Who Will Benefit: Upcoming Webinars: Regulatory Affairs Personnel Quality Personnel Clinical Personnel Research Personnel Laboratory Personnel Manufacturing Personnel Legal Personnel Clinical Research Associates Personnel who require a general understanding of the FDAs Expedited Programs for serious conditions Drugs and Medical Devices Available Recorded Webinars: Register Now Root Cause Analysis and Corrective Action Good Laboratory Practice Regulations process for drugs, biologics, medical devices and generic drugs. He has worked in every major segment of the industry-research, quality assurance, regulatory affairs, manufacturing and clinical. He lectures throughout the world on numerous FDA related matters. He is a consultant to FDA and trains FDA Field Force (those who conduct FDA inspections) on GCP, GLP and GMP). In recent years he has filed numerous FDA drug, biologic and medical device submissions for product approval. Quality by Design (QbD) Across the Product Lifecycle How to Implement HIPAA Requirements in GxP Regulated Establishments Risk Management Principles FDA Adverse Event Reporting forFDA Adverse Event Reporting for PRO versionpdfcrowd.com Are you a developer? Try out the HTML to PDF APIHTML to PDF API

It would be really nice if you can share this mail to all your colleagues who can get benefit from this training. Home Home | About Us | Contact Us | Terms of Use | Priv acy PolicyAbout Us Contact Us Terms of Use Priv acy Policy Call Us : | us : Uns ubs cribe About Compliance Trainings: Compliance Trainings focuses on providing regulatory and quality based trainings to industry professionals across the globe. Compliance Trainings strive to educate and enhance the knowledge and broaden the horizons of regulatory professionals as well as professionals from the HR, Healthcare and many other industries. Compliance Trainings intends to establish both, a strategic and significant hold in the training industry by providing the highest level of quality trainings and consulting. To achieve our goal, Compliance Trainings uses the latest technology to make trainings both affordable as well as relevant to the industries professionals who work in an ever changing and highly regulated environment. 10 Steps to Perfect SOPs: FDA10 Steps to Perfect SOPs: FDA Acceptable SOPs made Easy Sign Up with Us to get:Sign Up with Us to get: Weekly Newsletters Regular updateson Trending topics and discussions Onlinetrainingsessions by Industry Experts PRO versionpdfcrowd.com Are you a developer? Try out the HTML to PDF APIHTML to PDF API